Rofecoxib
SIGMA/SML0613 - ≥98% (HPLC)
Synonym: 4-
CAS Number: 162011-90-7
Empirical Formula (Hill Notation): C17H14O4S
Molecular Weight: 314.36
Linear Formula: C17H14O4S
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C17H14O4S/c1-22(19,20) |
| InChI key | RZJQGNCSTQAWON-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | [S](=O)(=O)(C)c1ccc(cc1)C |
| solubility | DMSO: 5 mg/mL, clear (warmed) |
| storage temp. | 2-8°C |
| Application: | Rofecoxib has been used in high performance bioaffinity chromatography. |
| Biochem/physiol Actions: | Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with >800-fold COX-2 selectivity in CHO cells expressing human COX-1 and COX-2. |
| Biochem/physiol Actions: | Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor. |
| Biochem/physiol Actions: | Rofecoxib is derived from furanone and has the ability to cross human placenta. Along with anti-inflammatory action, it possesses analgesic and antipyretic properties. Cytosolic hepatic enzymes are responsible for the metabolism of rofecoxib. It is known to cause oligohydramnios and ductus arteriosus constrictions. Rofecoxib inhibits the action of CYP1A2 (cytochrome P450 family 1 subfamily A member 2). It might be associated with aseptic meningitis. Rofecoxib is known to ameliorate the risk of colorectal adenoma, but might contribute to toxicity. |
| Packaging: | 10, 50 mg in glass bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Hazard Codes | Xn |
| Risk Statements | 22 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


